Keros Therapeutics Inc
KROS14.650USD
+0.330+2.30%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
594.23MCap. mercado
141.08P/E TTM
Más Datos de Keros Therapeutics Inc Compañía
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Información de la empresa
Símbolo de cotizaciónKROS
Nombre de la empresaKeros Therapeutics Inc
Fecha de salida a bolsaApr 08, 2020
Director ejecutivoDr. Jasbir Seehra, Ph.D.
Número de empleados169
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 08
Dirección1050 Waltham Street, Suite 302
CiudadLEXINGTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02421
Teléfono16173146297
Sitio Webhttps://www.kerostx.com/
Símbolo de cotizaciónKROS
Fecha de salida a bolsaApr 08, 2020
Director ejecutivoDr. Jasbir Seehra, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
302.22K
+19.52%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Lead Independent Director
Lead Independent Director
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Mr. Tomer Kariv, J.D.
Mr. Tomer Kariv, J.D.
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Christopher R. Rovaldi
Mr. Christopher R. Rovaldi
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
302.22K
+19.52%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Lead Independent Director
Lead Independent Director
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Mr. Tomer Kariv, J.D.
Mr. Tomer Kariv, J.D.
Independent Director
Independent Director
5.25K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 27 de jul
Actualizado: dom., 27 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Adar1 Capital Management LLC
13.27%
Pontifax Venture Capital
11.79%
Madison Avenue Partners LP
6.44%
J.P. Morgan Securities LLC
6.32%
The Vanguard Group, Inc.
6.32%
Other
55.86%
Accionistas
Accionistas
Proporción
Adar1 Capital Management LLC
13.27%
Pontifax Venture Capital
11.79%
Madison Avenue Partners LP
6.44%
J.P. Morgan Securities LLC
6.32%
The Vanguard Group, Inc.
6.32%
Other
55.86%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
38.34%
Investment Advisor
21.28%
Investment Advisor/Hedge Fund
18.66%
Venture Capital
17.81%
Research Firm
10.83%
Private Equity
2.51%
Corporation
1.41%
Individual Investor
0.93%
Sovereign Wealth Fund
0.16%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
390
45.97M
113.19%
-7.37M
2025Q1
394
39.41M
98.81%
-8.43M
2024Q4
366
43.10M
106.25%
-873.01K
2024Q3
351
43.05M
114.83%
+404.61K
2024Q2
337
39.69M
109.09%
-4.15M
2024Q1
332
39.81M
110.03%
+1.08M
2023Q4
310
34.40M
109.87%
-229.62K
2023Q3
303
31.04M
104.70%
-2.97M
2023Q2
305
30.88M
104.58%
-2.59M
2023Q1
303
30.13M
102.36%
-2.18M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Adar1 Capital Management LLC
5.39M
13.27%
--
--
May 12, 2025
Pontifax Venture Capital
4.79M
11.79%
--
--
Apr 17, 2025
Madison Avenue Partners LP
2.61M
6.44%
+2.61M
--
May 14, 2025
J.P. Morgan Securities LLC
2.57M
6.32%
+2.38M
+1301.87%
Mar 31, 2025
The Vanguard Group, Inc.
2.57M
6.32%
+616.06K
+31.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.51M
6.18%
+40.82K
+1.65%
Mar 31, 2025
Logos Global Management LP
2.00M
4.92%
+2.00M
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.51M
3.71%
+591.74K
+64.67%
Mar 31, 2025
State Street Global Advisors (US)
1.30M
3.21%
+99.16K
+8.24%
Mar 31, 2025
D. E. Shaw & Co., L.P.
1.26M
3.11%
+1.25M
+10339.95%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Janus Henderson Small Cap Growth Alpha ETF
1.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.79%
Federated Hermes MDT Small Cap Core ETF
0.45%
ALPS Medical Breakthroughs ETF
0.37%
SPDR S&P Biotech ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Biotechnology ETF
0.05%
Ver más
Janus Henderson Small Cap Growth Alpha ETF
Proporción1.06%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.88%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporción0.79%
Federated Hermes MDT Small Cap Core ETF
Proporción0.45%
ALPS Medical Breakthroughs ETF
Proporción0.37%
SPDR S&P Biotech ETF
Proporción0.18%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.1%
Invesco Nasdaq Biotechnology ETF
Proporción0.06%
ProShares Ultra Nasdaq Biotechnology
Proporción0.06%
iShares Biotechnology ETF
Proporción0.05%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
